2026
conference-abstract
OpenAlex
S. Shivhare, Caren I. Sanchez, Richard Larson, Lacey E. Dobrolecki et autres
Abstract Purpose: Inflammatory breast cancer (IBC) is a rare, highly aggressive subtype marked by rapid proliferation, extensive angio-/lymphangiogenesis, and early metastasis. CCR7, a chemokine receptor involved in immune trafficking, promotes tumor migration toward lymphatics via CCL19/CCL21. This study provides an integrated genomic, …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Clinton Yam, T. Iwase, B. Nelson, R. L. Bassett et autres
Abstract Background: Pts with residual disease (non-pCR) after the KEYNOTE-522 regimen face a 30-40% risk of recurrence within 3 years, underscoring the urgent need for more effective therapies. In preliminary analyses, we identified that ≤80% tumor reduction after 4 cycles of paclitaxel+carboplatin …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
E. R. Lopez, A. Singareeka Raghavendra, Sarah Pasyar, B. Lim et autres
Abstract BACKGROUND The benefit of chemotherapy in very early-stage triple-negative breast cancer (TNBC) remains unclear, as these patients have historically been excluded from clinical trials. Guidelines recommend consideration of chemotherapy for T1b tumors (0.6-1 cm) and is not recommend for T1a tumors …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
S. Shivhare, C. Sanchez, R. Larson, L. Dobrolecki et autres
Abstract Purpose: Inflammatory breast cancer (IBC) is a rare yet exceptionally aggressive subtype that accounts for a disproportionate number of breast cancer deaths. A significant barrier to effective treatment is its ability to invade the lymphatic system and evade immune suppression. Emerging …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
S. Murray, A. Nasrazadani, Clinton Yam, A. Alexander et autres
Abstract Background: Inflammatory breast cancer (IBC) is a rare and aggressive subtype with poor outcomes, particularly in patients with residual disease post-neoadjuvant therapy. Antibody-drug conjugates (ADCs), such as sacituzumab govitecan (SG), have shown efficacy in hard-to-treat subtypes like TNBC and HR+/HER2- disease. …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Clinton Yam, Anastasia Radko, L. Huo, S. Akshara et autres
Abstract Background: The incorporation of immune checkpoint inhibitors, specifically pembrolizumab (anti-PD-1), into neoadjuvant therapy, has improved outcomes for patients with stage II-III triple-negative breast cancer (TNBC). However, due to the risk of of immune-related adverse events, there remains a critical need to …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
E. P. Mamounas, Hanna Bandos, K. J. Sweeney, K. M. Tran et autres
Abstract Background: SETER/PR index of sensitivity to endocrine therapy (ET) measures endocrine receptor-related transcription from fixed paraffin-embedded tissue and is highly reproducible within and between laboratories. SETER/PR index is correlated with receptor ligand binding activity and predicts early pharmacodynamic response to ET …
us, ca, ie, kr
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
E. Onwubiko, Megumi Kai, M. C. Stauder, S. X. Sun et autres
Abstract Purpose: This study examines the clinical outcomes for Inflammatory Breast Cancer (IBC) patients who develop locoregional recurrence (LRR) after tri-modality therapy (TMT), including systemic therapy, modified radical mastectomy and post-mastectomy radiation therapy (PMRT). While LRR is uncommon after standard trimodal therapy …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Mark Basik, Emilia J. Diego, G. Tang, S. Puhalla et autres
Abstract Background: Detection of occult micrometastatic cancer—molecular residual disease (MRD)—in patients following treatment for high-risk phenotypes of early breast cancer using circulating tumor DNA (ctDNA) is associated with a high risk of recurrence. An ultra-sensitive, tumor-informed, whole-genome, minor-allele-enriched sequencing through recognition oligonucleotides …
ca, us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
A. Singareeka Raghavendra, Z. WANG, R. Bssett, S. Damodaran et autres
Abstract Background: The antibody-drug conjugate sacituzumab govitecan (SG) is approved for patients with metastatic triple-negative breast cancer (mTNBC) and hormone receptor (HR)+/Human epidermal growth factor receptor 2 (HER2)- metastatic breast cancer (mBC). The impact of HER2-low status on treatment outcomes remains unclear. …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
V. Valero, Z. WANG, R. L. Bassett, R. K. MURTHY et autres
Abstract Background: HER2-positive metastatic breast cancer (MBC) remains an oncological challenge afterdisease progression to pertuzumab-trastuzumab, and fam-trastuzumab deruxtecan. Data on treatmentoutcomes with T-DM1 following progression on trastuzumab deruxtecan (T-DXd) remain limited. This study evaluates the clinical outcomes of patients with HER2-positive MBC …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
S. Krishnamurthy, R. S. Tidwell, Megumi Kai, L. Villareal et autres
Abstract Background: Current guidelines do not mandate routine evaluation of ER, PR, and HER2 in residual tumor after neoadjuvant therapy (NAT), including chemotherapy, targeted therapy, and immune checkpoint inhibitors, in breast cancer. There are no studies that evaluated the stability of these …
us
(code pays fourni par la source)